<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192776</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0043</org_study_id>
    <secondary_id>U10HD021364</secondary_id>
    <secondary_id>U10HD021373</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD027871</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD034216</secondary_id>
    <secondary_id>U10HD036790</secondary_id>
    <secondary_id>U10HD040492</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD053089</secondary_id>
    <secondary_id>U10HD053109</secondary_id>
    <secondary_id>U10HD053119</secondary_id>
    <secondary_id>U10HD053124</secondary_id>
    <secondary_id>UL1RR024139</secondary_id>
    <secondary_id>UL1RR024979</secondary_id>
    <secondary_id>UL1RR025008</secondary_id>
    <secondary_id>UL1RR025744</secondary_id>
    <secondary_id>UL1RR025747</secondary_id>
    <secondary_id>UL1RR025761</secondary_id>
    <secondary_id>UL1RR025764</secondary_id>
    <secondary_id>U10HD068284</secondary_id>
    <secondary_id>U10HD068278</secondary_id>
    <secondary_id>U10HD068270</secondary_id>
    <secondary_id>U10HD068263</secondary_id>
    <secondary_id>U10HD068244</secondary_id>
    <nct_id>NCT01192776</nct_id>
  </id_info>
  <brief_title>Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)</brief_title>
  <official_title>Optimizing Cooling Strategies at &lt; 6 Hours of Age for Neonatal Hypoxic-Ischemic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Optimizing Cooling trial will compare four whole-body cooling treatments for infants born
      at 36 weeks gestational age or later with hypoxic-ischemic encephalopathy: (1) cooling for 72
      hours to 33.5°C; (2) cooling for 120 hours to 33.5°C; (3) cooling for 72 hours to 32.0°C; and
      (4) cooling for 120 hours to 32.0°C. The objective of this study is to evaluate whether
      whole-body cooling initiated at less than 6 hours of age and continued for 120 hours and/or a
      depth at 32.0°C in will reduce death and disability at 18-22 months corrected age.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypoxic-ischemic encephalopathy (HIE) is a rare, but life-threatening condition characterized
      by brain injury due to asphyxia diagnosed at or shortly after birth. According to the World
      Health Organization, more than 722,000 children died from birth asphyxia and birth trauma
      worldwide in 2004. An estimated 50-75 percent of infants with severe (stage 3) HIE will die,
      with 55 percent of these deaths occurring in the first month. Up to 80 percent of infants who
      survive stage 3 HIE develop significant long-term disabilities, including intellectual
      disabilities, epilepsy, and cerebral palsy with hemiplegia, paraplegia, or quadriplegia;
      10-20 percent develop moderately serious disabilities; and up to 10 percent are normal.

      Previous studies have shown treatment with hypothermia to be an effective therapy for HIE.
      Currently, infants diagnosed with HIE at less than six hours of age are given whole-body
      cooling, decreasing their core body temperature to 33.5°C (93.2° Fahrenheit) for a period 72
      hours using a cooling blanket. This treatment appears to protect the brain, decreasing the
      rate of death and disability and improving the chances of survival and neurodevelopmental
      outcomes at 18 months correct age. But additional trials are needed to help define the most
      effective cooling strategies.

      The Optimizing Cooling trial will examine whether cooling for a longer time period and/or to
      a lower temperature will improve the chance of survival and neurodevelopmental outcomes at
      18-22 months corrected age. Eligible infants with HIE will be placed in one of four cooling
      groups: (1) cooling for 72 hours to 33.5°C; (2) cooling for 120 hours to 33.5°C; (3) cooling
      for 72 hours to 32.0°C; and (4) cooling for 120 hours to 32.0°C. Infants will be monitored
      closely and receive the care of the Neonatal Intensive Care Unit (NICU).

      Infants enrolled in the study will be placed on a cooling blanket - the same type of blanket
      children's hospitals use in the NICU, in operating rooms during surgeries, and to cool
      children with high fevers. Each infant will be cooled according to the study group he or she
      is assigned to. During cooling, the infant's temperature will be very closely monitored by
      continuous esophageal (core)temperature readings. This will be done by placing a soft,
      narrow, flexible plastic tube into the infant's nose and down to just above the stomach. Skin
      temperatures will also be monitored closely. At the end of the assigned period of cooling,
      the infant will be slowly re-warmed until a normal core temperature of 36.5 to 37.0°C (97.7
      to 98.6°C) is reached.

      Infants will be examined at 18-22 months corrected age to assess their neurodevelopmental
      outcomes.

      Secondary Studies include:

      A. Using aEEG to 1)predict mortality or moderate to severe disability at 18-22 months in term
      infants with HIE treated with systemic hypothermia and 2) to record electrical seizure
      activity to compare rewarming initiated at 72 hours and later rewarming that is initiated at
      120 hours.

      B. Secondary Study includes determining an association between MRI detectable injury and
      neurodevelopment at 18-22 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial closed for emerging safety profile and futility analysis and will not resume.
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Moderate to Severe Disability</measure>
    <time_frame>Birth to 22 months corrected age</time_frame>
    <description>Death includes any mortality prior to follow up at 18-22 months. Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Birth to 22 months corrected age</time_frame>
    <description>Death includes any mortality prior to follow up at 18-22 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Disability Among Survivors</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Among survivors number of normal infants and infants with mild, moderate, and severe disability
Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal of Care</measure>
    <time_frame>Birth through hospital discharge, average 22 days.</time_frame>
    <description>Number of infants for whom aggressive care is withdrawn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Neonatal Seizures</measure>
    <time_frame>Through death, discharge, or transfer</time_frame>
    <description>Documented seizures during hospital course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley Cognitive Score</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Bayley Scale of Infant Development Composite Cognitive Score. The total composite score is reported, ranging from the lowest score of 55 to the highest score of 145. Lower values specify worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Palsy</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Disability Among Survivors, by Level of HIE</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Among survivors, number of normal infants and infants with mild, moderate and severe disability Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Impairment</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Visual impairment is defined as bilateral blindness with some/no useful vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hearing Impairment</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Hearing impairment is defined as hearing impairment despite amplification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Disabilities</measure>
    <time_frame>Follow up at 18-22 months corrected age</time_frame>
    <description>Multiple disabilities is defined as two or more of the following 5 components: disabling CP, GMFCS level 3-5, Bayley cognitive score &lt; 70, blindness, or deafness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiorgan Dysfunction</measure>
    <time_frame>Until death, discharge, or transfer</time_frame>
    <description>The data needed for this analysis are not collected directly, and needs to be coded based on the available information. This is a complex undertaking and will take additional time to create. Once created, we will promptly report the results and anticipate reporting by March 2018.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severe Neonatal Brain Abnormalities</measure>
    <time_frame>7-14 days of life</time_frame>
    <description>The data for this analysis have not yet been collected.
MRIs taken between 7-14 days will be examined.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Infant, Newborn</condition>
  <condition>Hypoxia, Brain</condition>
  <condition>Hypoxia-Ischemia, Brain</condition>
  <condition>Encephalopathy, Hypoxic-Ischemic</condition>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <condition>Ischemic-Hypoxic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>33.5°C for 72 hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Target Temp: 33.5°C Duration: 72 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>33.5°C for 120 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Temp: 33.5°C Duration: 120 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>32.0°C for 72 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Temp: 32.0°C Duration: 72 hrs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>32.0°C for 120 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Temp: 32.0°C Duration:120 hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Whole-body Cooling</intervention_name>
    <description>Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
    <arm_group_label>33.5°C for 72 hours</arm_group_label>
    <arm_group_label>33.5°C for 120 hours</arm_group_label>
    <arm_group_label>32.0°C for 72 hours</arm_group_label>
    <arm_group_label>32.0°C for 120 hours</arm_group_label>
    <other_name>Blanketrol II Model 222R</other_name>
    <other_name>Blanketrol III Model 233 (used in the II mode)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligibility will be determined in a stepped process:

          1. All infants with a gestational age ≥ 36 weeks will be screened for study entry if they
             are admitted to the NICU with a diagnosis of fetal acidosis, perinatal asphyxia,
             neonatal depression or encephalopathy.

          2. Infants will be eligible if:

               -  They have a pH ≤ 7.0 or a base deficit ≥ 16m mEq/ L on umbilical cord or any
                  postnatal sample within 1 hour of age.

               -  If, during this interval, they have a pH between 7.01 and 7.15, a base deficit is
                  between 10 and 15.9 mEq/L, or a blood gas is not available, AND they have an
                  acute perinatal event AND either a 10-minute Apgar score ≤ 5 or assisted
                  ventilation initiated at birth and continued for at least 10 minutes.

          3. Once these criteria are met, eligible infants will have a standardized neurological
             examination performed by a certified physician examiner. Infants will be candidates
             for the study when encephalopathy or seizures are present. For this study,
             encephalopathy is defined as the presence of 1 or more signs in 3 of the following 6
             categories:

               -  Level of consciousness: lethargy, stupor or coma;

               -  Spontaneous activity: decreased, absent;

               -  Posture: distal flexion, decerebrate;

               -  tone: hypotonia, flaccid or hypertonia, rigid;

               -  Primitive reflexes: a) suck, weak, absent; b) Moro, incomplete, flaccid;

               -  Autonomic nervous system: a) pupils: constricted, unequal, skew deviation or non
                  reactive to light; b) heart rate: bradycardia, variable heart rate or c)
                  respiration: periodic breathing, apnea.

        Eligible infants from multiple births will be enrolled in the same arm of the study.

        Exclusion Criteria:

          -  Inability to randomize by 6 hours of age

          -  Major congenital abnormality

          -  Major chromosomal abnormality (including Trisomy 21),

          -  Severe growth restriction (≤ 1800gm birth weight),

          -  Infant is moribund and will not receive any further aggressive treatment,

          -  Refusal of consent by parent

          -  Refusal of consent by attending neonatologist

          -  Infants with a core temperature &lt; 33.5°C for &gt; 1 hour at the time of screening by the
             research team would not be eligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abbot R Laptook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Women &amp; Infants Hospital of Rhode Island</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele C Walsh, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University, Rainbow Babies and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald N. Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J. Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brenda B. Poindexter, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhik Das, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTI International</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krisa P. Van Meurs, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Schibler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waldemar A. Carlo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F. Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristi L. Watterberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pablo J. Sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen A. Kennedy, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Truog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Schmidt, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carl D'Angio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uday Devaskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leif Nelin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute at Nationwide Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTI International</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute at Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org</url>
    <description>Neonatal Research Network website</description>
  </link>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>July 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2017</results_first_posted>
  <last_update_submitted>September 5, 2017</last_update_submitted>
  <last_update_submitted_qc>September 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NICHD Neonatal Research Network</keyword>
  <keyword>Hypoxic-ischemic encephalopathy (HIE)</keyword>
  <keyword>Hypothermia</keyword>
  <keyword>Neonatal depression</keyword>
  <keyword>Perinatal asphyxia</keyword>
  <keyword>Fetal acidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Publication</doc_type>
      <doc_url>http://www.ncbi.nlm.nih.gov/pubmed/25536254</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1261 infants assessed for eligibility. 897 were excluded for not meeting eligibility criteria (N=747) or not having parental or physician consent (N=150).</recruitment_details>
      <pre_assignment_details>All eligible infants with consent were randomized to one of four treatment arms/groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>33.5°C for 72 Hours</title>
          <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="P2">
          <title>32.0°C for 72 Hours</title>
          <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="P3">
          <title>33.5°C for 120 Hours</title>
          <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="P4">
          <title>32.0°C for 120 Hours</title>
          <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Died Prior to Discharge</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Died After Discharge</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>33.5°C for 72 Hours</title>
          <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="B2">
          <title>32.0°C for 72 Hours</title>
          <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="B3">
          <title>33.5°C for 120 Hours</title>
          <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="B4">
          <title>32.0°C for 120 Hours</title>
          <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="90"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="83"/>
            <count group_id="B5" value="364"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at Randomization</description>
          <population>Data was missing for one participant.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="1.0"/>
                    <measurement group_id="B2" value="4.9" spread="1.2"/>
                    <measurement group_id="B3" value="4.8" spread="1.1"/>
                    <measurement group_id="B4" value="5.0" spread="1.6"/>
                    <measurement group_id="B5" value="4.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ambiguous</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Data was missing for six participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="94"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="94"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="89"/>
                    <count group_id="B3" value="94"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birthweight</title>
          <population>Data was missing for one participant.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="95"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3230" spread="528"/>
                    <measurement group_id="B2" value="3360" spread="544"/>
                    <measurement group_id="B3" value="3354" spread="676"/>
                    <measurement group_id="B4" value="3511" spread="615"/>
                    <measurement group_id="B5" value="3359" spread="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Level of encephalopathy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="95"/>
                    <count group_id="B2" value="90"/>
                    <count group_id="B3" value="96"/>
                    <count group_id="B4" value="83"/>
                    <count group_id="B5" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="280"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Moderate to Severe Disability</title>
        <description>Death includes any mortality prior to follow up at 18-22 months. Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands.</description>
        <time_frame>Birth to 22 months corrected age</time_frame>
        <population>Includes all deaths and all infants followed at 18-22 months. Does not include 17 infants lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Moderate to Severe Disability</title>
          <description>Death includes any mortality prior to follow up at 18-22 months. Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands.</description>
          <population>Includes all deaths and all infants followed at 18-22 months. Does not include 17 infants lost to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.53</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Death includes any mortality prior to follow up at 18-22 months.</description>
        <time_frame>Birth to 22 months corrected age</time_frame>
        <population>Includes all deaths and all infants followed at 18-22 months. Does not include 17 infants lost to follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death includes any mortality prior to follow up at 18-22 months.</description>
          <population>Includes all deaths and all infants followed at 18-22 months. Does not include 17 infants lost to follow up.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>8.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>2.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>5.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>4.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Disability Among Survivors</title>
        <description>Among survivors number of normal infants and infants with mild, moderate, and severe disability
Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Includes all infants followed at 18-22 months except for 6 infants who could not be distinguished between normal and mild. Does not include 17 infants lost to follow up or 56 deaths</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Disability Among Survivors</title>
          <description>Among survivors number of normal infants and infants with mild, moderate, and severe disability
Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
          <population>Includes all infants followed at 18-22 months except for 6 infants who could not be distinguished between normal and mild. Does not include 17 infants lost to follow up or 56 deaths</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Severe disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal of Care</title>
        <description>Number of infants for whom aggressive care is withdrawn</description>
        <time_frame>Birth through hospital discharge, average 22 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal of Care</title>
          <description>Number of infants for whom aggressive care is withdrawn</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Neonatal Seizures</title>
        <description>Documented seizures during hospital course</description>
        <time_frame>Through death, discharge, or transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Neonatal Seizures</title>
          <description>Documented seizures during hospital course</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bayley Cognitive Score</title>
        <description>Bayley Scale of Infant Development Composite Cognitive Score. The total composite score is reported, ranging from the lowest score of 55 to the highest score of 145. Lower values specify worse outcome.</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Infants who survived and were followed at 18-22 months</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Bayley Cognitive Score</title>
          <description>Bayley Scale of Infant Development Composite Cognitive Score. The total composite score is reported, ranging from the lowest score of 55 to the highest score of 145. Lower values specify worse outcome.</description>
          <population>Infants who survived and were followed at 18-22 months</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="90" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O3" value="90" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O4" value="90" lower_limit="80" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebral Palsy</title>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Infants who survived and were followed at 18-22 months</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebral Palsy</title>
          <population>Infants who survived and were followed at 18-22 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>2.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Disability Among Survivors, by Level of HIE</title>
        <description>Among survivors, number of normal infants and infants with mild, moderate and severe disability Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Includes all infants followed at 18-22 months, except for 6 infants who could not be distinguished between normal and mild. Does not include 17 infants lost to follow up or 56 deaths.</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Level of Disability Among Survivors, by Level of HIE</title>
          <description>Among survivors, number of normal infants and infants with mild, moderate and severe disability Severe disability was defined by any of the following: a Bayley III cognitive score &lt;70, a GMFCS level of 3-5, blindness or profound hearing loss (inability to understand commands despite amplification). Moderate disability was defined as a Bayley cognitive score of 70-84 and either a GMFCS level of 2, seizure disorder, or a hearing deficit requiring amplification to understand commands. Mild impairment was defined by a cognitive score 70-84, or a cognitive score ≥ 85 and any of the following: presence of a GMFCS level 1 or 2, seizure disorder or hearing loss not requiring amplification. Normal was defined by a cognitive score ≥ 85 in the absence of any neurosensory deficits or seizures after NICU discharge.</description>
          <population>Includes all infants followed at 18-22 months, except for 6 infants who could not be distinguished between normal and mild. Does not include 17 infants lost to follow up or 56 deaths.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Moderate HIE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="65"/>
                    <count group_id="O4" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe HIE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe disability</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Impairment</title>
        <description>Visual impairment is defined as bilateral blindness with some/no useful vision</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Infants who survived and were followed at 18-22 months</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Impairment</title>
          <description>Visual impairment is defined as bilateral blindness with some/no useful vision</description>
          <population>Infants who survived and were followed at 18-22 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>2.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hearing Impairment</title>
        <description>Hearing impairment is defined as hearing impairment despite amplification</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Infants who survived and were followed at 18-22 months</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Hearing Impairment</title>
          <description>Hearing impairment is defined as hearing impairment despite amplification</description>
          <population>Infants who survived and were followed at 18-22 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>3.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>3.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>2.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Disabilities</title>
        <description>Multiple disabilities is defined as two or more of the following 5 components: disabling CP, GMFCS level 3-5, Bayley cognitive score &lt; 70, blindness, or deafness.</description>
        <time_frame>Follow up at 18-22 months corrected age</time_frame>
        <population>Infants who survived and were followed at 18-22 months</population>
        <group_list>
          <group group_id="O1">
            <title>33.5°C for 72 Hours</title>
            <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O2">
            <title>32.0°C for 72 Hours</title>
            <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O3">
            <title>33.5°C for 120 Hours</title>
            <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
          <group group_id="O4">
            <title>32.0°C for 120 Hours</title>
            <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Disabilities</title>
          <description>Multiple disabilities is defined as two or more of the following 5 components: disabling CP, GMFCS level 3-5, Bayley cognitive score &lt; 70, blindness, or deafness.</description>
          <population>Infants who survived and were followed at 18-22 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 72 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>2.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>33.5°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>32.0°C for 120 hours vs. 33.5°C for 72 hours (33.5°C for 72 hours is the comparison group)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Generalized Estimating Equations models with log link, adjusted for level of encephalopathy and intra-center correlations</non_inferiority_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.13</ci_lower_limit>
            <ci_upper_limit>1.64</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiorgan Dysfunction</title>
        <description>The data needed for this analysis are not collected directly, and needs to be coded based on the available information. This is a complex undertaking and will take additional time to create. Once created, we will promptly report the results and anticipate reporting by March 2018.</description>
        <time_frame>Until death, discharge, or transfer</time_frame>
        <posting_date>03/2018</posting_date>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severe Neonatal Brain Abnormalities</title>
        <description>The data for this analysis have not yet been collected.
MRIs taken between 7-14 days will be examined.</description>
        <time_frame>7-14 days of life</time_frame>
        <posting_date>07/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During study intervention period: 72 or 120 hours from baseline, based on treatment arm</time_frame>
      <desc>17 infants lost to follow up were excluded from the All-Cause Mortality table. Mortality cannot be assessed for infants lost to follow up.</desc>
      <group_list>
        <group group_id="E1">
          <title>33.5°C for 72 Hours</title>
          <description>Target Temp: 33.5°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="E2">
          <title>32.0°C for 72 Hours</title>
          <description>Target Temp: 32.0°C Duration: 72 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="E3">
          <title>33.5°C for 120 Hours</title>
          <description>Target Temp: 33.5°C Duration: 120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
        <group group_id="E4">
          <title>32.0°C for 120 Hours</title>
          <description>Target Temp: 32.0°C Duration:120 hrs
Whole-body Cooling: Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Other Serious Adverse Events</description>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" events="16" subjects_affected="11" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death during intervention</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic acidosis developing &gt;3 hours after initiation of intervention and persisting &gt;3 hours</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alteration of Skin Integrity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators must adhere to the Neonatal Research Network Publication policies.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This RCT was stopped for safety and futility reasons by the Data Safety and Monitoring Committee so did not enroll the target number of participants needed to achieve target power and statistically reliable results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Seetha Shankaran</name_or_title>
      <organization>Wayne State University</organization>
      <phone>(313) 745-1436</phone>
      <email>sshankar@med.wayne.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

